- Home
- LYEL
as of 02-24-2026 3:39pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 548.9M | IPO Year: | 2021 |
| Target Price: | $25.00 | AVG Volume (30 days): | 89.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.38 | EPS Growth: | -40.86 |
| 52 Week Low/High: | $0.39 - $45.00 | Next Earning Date: | 01-01-0001 |
| Revenue: | $61,000 | Revenue Growth: | -53.08% |
| Revenue Growth (this year): | -62.38% | Revenue Growth (next year): | N/A |
| P/E Ratio: | -2.71 | Index: | N/A |
| Free Cash Flow: | -162858000.0 | FCF Growth: | N/A |
AI-Powered LYEL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)
Chief Operating Officer
Avg Cost/Share
$23.39
Shares
1,236
Total Value
$28,910.04
Owned After
17,795
SEC Form 4
President and CEO
Avg Cost/Share
$23.39
Shares
7,455
Total Value
$174,372.45
Owned After
74,266
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$23.39
Shares
1,671
Total Value
$39,084.69
Owned After
16,938
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$23.12
Shares
109
Total Value
$2,520.08
Owned After
17,795
SEC Form 4
President and CEO
Avg Cost/Share
$23.12
Shares
438
Total Value
$10,126.56
Owned After
74,266
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$23.12
Shares
147
Total Value
$3,398.64
Owned After
16,938
SEC Form 4
VP, Corporate Controller
Avg Cost/Share
$23.12
Shares
254
Total Value
$5,872.48
Owned After
15,637
SEC Form 4
VP, Corporate Controller
Avg Cost/Share
$32.32
Shares
936
Total Value
$30,251.52
Owned After
15,637
SEC Form 4
VP, Corporate Controller
Avg Cost/Share
$38.67
Shares
1,136
Total Value
$43,929.12
Owned After
15,637
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hill Stephen J. | LYEL | Chief Operating Officer | Feb 11, 2026 | Sell | $23.39 | 1,236 | $28,910.04 | 17,795 | |
| Seely Lynn | LYEL | President and CEO | Feb 11, 2026 | Sell | $23.39 | 7,455 | $174,372.45 | 74,266 | |
| Lee Gary K. | LYEL | Chief Scientific Officer | Feb 11, 2026 | Sell | $23.39 | 1,671 | $39,084.69 | 16,938 | |
| Hill Stephen J. | LYEL | Chief Operating Officer | Feb 10, 2026 | Sell | $23.12 | 109 | $2,520.08 | 17,795 | |
| Seely Lynn | LYEL | President and CEO | Feb 10, 2026 | Sell | $23.12 | 438 | $10,126.56 | 74,266 | |
| Lee Gary K. | LYEL | Chief Scientific Officer | Feb 10, 2026 | Sell | $23.12 | 147 | $3,398.64 | 16,938 | |
| Bulis Veronica Sanchez | LYEL | VP, Corporate Controller | Feb 10, 2026 | Sell | $23.12 | 254 | $5,872.48 | 15,637 | |
| Bulis Veronica Sanchez | LYEL | VP, Corporate Controller | Dec 30, 2025 | Sell | $32.32 | 936 | $30,251.52 | 15,637 | |
| Bulis Veronica Sanchez | LYEL | VP, Corporate Controller | Dec 24, 2025 | Sell | $38.67 | 1,136 | $43,929.12 | 15,637 |
Compare LYEL vs Leading Stocks
See how LYEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.